17
JUN
2024

Northwest Biotherapeutics Announces Exclusive In-License of Portfolio of Dendritic Cell Technology and Intellectual Property

Posted By :
Comments : Off
Complementary to Technology & IP Already Owned or In-Licensed; Significant Step in Building a Leading Dendritic Cell Franchise BETHESDA, MD, June 17, 2024 – Northwest Biotherapeutics (OTCQB: NWBO) (“NW Bio”), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced today that on June 12, 2024 it entered into an exclusive license from Roswell Park Comprehensive Cancer Center for a...
Read More
21
MAR
2024

Northwest Biotherapeutics Appoints Seasoned Business Executive and Investor to its Board of Directors

Posted By :
Comments : Off
BETHESDA, MD, March 21, 2024 – Northwest Biotherapeutics (OTCQB: NWBO) (“NW Bio”), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced today that it has appointed Mr. Pat Sarma to its Board of Directors effective March 18, 2024. Mr. Sarma will initially complete the remainder of Mr. Jerry Jasinowski’s term as an independent director, following Mr. Jasinowski’s retirement due...
Read More
06
FEB
2024

Northwest Biotherapeutics Moves From Optimization of Flaskworks Prototype to Fabrication of GMP-Compliant Units For Installation, Validation and Final Testing Prior to Regulatory Certification

Posted By :
Comments : Off
Accompanied by Broad Patent Coverage BETHESDA, MD, February 6, 2024 – Northwest Biotherapeutics (OTCQB: NWBO) (“NW Bio”), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced today that the key development work for the Flaskworks manufacturing system has been completed and an external vendor has been engaged to produce GMP-grade units of the system. In addition, the patent coverage of the...
Read More
21
DEC
2023

Northwest Biotherapeutics Announces that a Marketing Authorization Application has been Submitted to the UK MHRA For DCVax®-L for Glioblastoma

Posted By :
Comments : Off
Culmination Of Over 20 Years Of Research And Clinical Development BETHESDA, MD, December 21, 2023 – Northwest Biotherapeutics (OTCQB: NWBO) (“NW Bio”), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced today that a Marketing Authorization Application (MAA) was submitted yesterday to the Medicines and Healthcare Products Regulatory Agency (MHRA) in the UK for DCVax®-L for glioblastoma...
Read More
22
NOV
2023

Northwest Biotherapeutics Provides Update On Final Preparations for Marketing Authorization Application

Posted By :
Comments : Off
BETHESDA, MD, November 22, 2023 – Northwest Biotherapeutics (OTCQB: NWBO) (“NW Bio”), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, provided an update today about the final preparations for the Marketing Authorization Application (MAA) that will be submitted to the Medicines and Healthcare Products Regulatory Agency (MHRA)(the equivalent of the U.S. FDA) in the U.K. for commercial approval...
Read More